Jeon Eun Su, Song Hae Young, Kim Mi Ra, Moon Hyun Jung, Bae Yong Chan, Jung Jin Sup, Kim Jae Ho
Research Center for Ischemic Tissue Regeneration, Pusan National University, Busan 602-739, Republic of Korea.
J Lipid Res. 2006 Mar;47(3):653-64. doi: 10.1194/jlr.M500508-JLR200. Epub 2005 Dec 7.
Sphingosylphosphorylcholine (SPC) has been implicated in a variety of cellular responses, including proliferation and differentiation. In this study, we demonstrate that d-erythro-SPC, but not l-threo-SPC, stereoselectively stimulated the proliferation of human adipose tissue-derived mesenchymal stem cells (hADSCs), with a maximal increase at 5 microM, and increased the intracellular concentration of Ca(2+) (Ca(2+)) in hADSCs, which do not express known SPC receptors (i.e., OGR1, GPR4, G2A, and GPR12). The SPC-induced proliferation and increase in Ca(2+) were sensitive to pertussis toxin (PTX) and the phospholipase C (PLC) inhibitor U73122, suggesting that PTX-sensitive G proteins, Gi or Go, and PLC are involved in SPC-induced proliferation. In addition, SPC treatment induced the phosphorylation of c-Jun and extracellular signal-regulated kinase, and SPC-induced proliferation was completely prevented by pretreatment with the c-Jun N-terminal kinase (JNK)-specific inhibitor SP600125 but not with the MEK-specific inhibitor U0126. Furthermore, the SPC-induced proliferation and JNK activation were completely attenuated by overexpression of a dominant negative mutant of JNK2, and the SPC-induced activation of JNK was inhibited by pretreatment with PTX or U73122. Treatment of hADSCs with lysophosphatidic acid (LPA) receptor antagonist, Ki16425, had no impact on the SPC-induced increase in Ca(2+). However, SPC-induced proliferation was partially, but significantly, attenuated by pretreatment of the cells with Ki16425.These results indicate that SPC stimulates the proliferation of hADSCs through the Gi/Go-PLC-JNK pathway and that LPA receptors may be responsible in part for the SPC-induced proliferation.
鞘氨醇磷酸胆碱(SPC)与多种细胞反应有关,包括增殖和分化。在本研究中,我们证明d-赤藓糖型SPC而非l-苏阿糖型SPC能立体选择性地刺激人脂肪组织来源的间充质干细胞(hADSCs)增殖,在5 microM时增殖增加最大,并且能增加hADSCs细胞内Ca(2+)([Ca(2+)]i)的浓度,而hADSCs不表达已知的SPC受体(即OGR1、GPR4、G2A和GPR12)。SPC诱导的增殖及[Ca(2+)]i增加对百日咳毒素(PTX)和磷脂酶C(PLC)抑制剂U73122敏感,提示PTX敏感的G蛋白、Gi或Go以及PLC参与SPC诱导的增殖。此外,SPC处理诱导c-Jun和细胞外信号调节激酶磷酸化,c-Jun N末端激酶(JNK)特异性抑制剂SP600125预处理可完全阻止SPC诱导的增殖,而MEK特异性抑制剂U0126则不能。此外,JNK2显性负突变体的过表达可完全减弱SPC诱导的增殖和JNK激活,PTX或U73122预处理可抑制SPC诱导的JNK激活。用溶血磷脂酸(LPA)受体拮抗剂Ki16425处理hADSCs对SPC诱导的[Ca(2+)]i增加无影响。然而,Ki16425预处理细胞可部分但显著减弱SPC诱导的增殖。这些结果表明,SPC通过Gi/Go-PLC-JNK途径刺激hADSCs增殖,LPA受体可能部分参与SPC诱导的增殖。